News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AHF: Gilead Sciences, Inc. (GILD)’s Stribild Not Covered by NY Medicaid; State Also Explores ‘Prior Auth’ Status for AIDS Drug



9/24/2012 10:12:50 AM

WASHINGTON--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) today reported that the New York State Department of Health’s Medicaid program does NOT cover Gilead Sciences’ expensive new AIDS drug Stribild, its new four-in-one treatment combination, which was approved by the Food and Drug Administration (FDA) in early September and then immediately priced by Gilead at $28,500 per patient, per year, Wholesale Acquisition Cost (WAC). That price was over 35% more than Atripla, the company’s best selling combination HIV/AIDS treatment, and made Stribild the highest priced first line combination AIDS therapy.

Read at BioSpace.com


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES